Dendreon Corp fka DNDNQ

[walldiver]

Saul, it's going to be a tough call. We don't know the percentages in each arm who will have taken Tax. It's actually the recent enrollees who are survivors that will have the biggest effect on the interim data. They will have to be censored at the moment of unblinding for the interim data calculations. That will cloud up the p value. If the unblinding occurs sometime in October 2008, there will be anywhere from 225 to 240 patients who will have been enrolled for less than 24 months. The biggest positive factor, if Provenge does impact survival, will probably be the long-term survival of the earliest enrollees. They won't have to be censored at 36 months as the long-term survivors were in the 9901 and 9902A trials.